Carmenta gains licensing option for preeclampsia diagnostic tool

01/28/2013 | GenomeWeb Daily News (free registration)

Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY